Clinical Research Directory
Browse clinical research sites, groups, and studies.
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
Sponsor: Cereno Scientific AB
Summary
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension. Participants completing Treatment Period 1 (Week 36) will be re-randomized to continue or switch study treatment for Treatment Period 2 through Week 52.
Official title: A Phase 2b, Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study, to Compare the Efficacy and Safety/Tolerability of CS1 Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
126
Start Date
2026-09-15
Completion Date
2029-04-30
Last Updated
2026-08-12
Healthy Volunteers
No
Conditions
Interventions
CS1
160 mg delayed release capsules taken orally once daily in the evening
Placebo
Matching placebo capsules taken orally once daily in the evening